What SEC filings does OnKure Therapeutics, Inc. submit to the SEC?

OnKure Therapeutics, Inc. (OKUR) submits several types of SEC filings including Form 4 (insider transactions), Form 144 (proposed insider sales), 8-K reports (material events such as earnings releases, acquisitions, leadership changes), and periodic reports — the 10-Q (quarterly) and 10-K (annual). All filings are publicly available through SEC EDGAR.

What does a Form 4 filing tell me about OKUR?

A Form 4 for OKUR discloses a transaction by a company insider — typically a director, officer, or 10%+ shareholder. It shows the source-reported date, number of shares, price, and updated ownership. These facts do not establish motive or predict future returns.

How do I interpret an 8-K filing from OnKure Therapeutics, Inc.?

An 8-K signals a material event requiring prompt disclosure. Common triggers include earnings pre-announcements, acquisitions, leadership appointments or departures, credit changes, or regulatory actions. Read the item codes inside the filing to understand exactly what was disclosed before drawing conclusions.

What is the difference between a 10-K and 10-Q for OKUR?

The 10-K is OnKure Therapeutics, Inc.'s annual report with fully audited financial statements, comprehensive MD&A, and complete risk factor disclosures — filed 60–90 days after fiscal year-end. The 10-Q is a lighter quarterly report with unaudited financials filed for the first three quarters. Together they provide a continuous financial picture of the company.

Where can I see all OKUR SEC filings directly on EDGAR?

You can view all historical OnKure Therapeutics, Inc. filings on the SEC EDGAR company page for OKUR. Each filing card on this page links directly to the original SEC document.

How often does OnKure Therapeutics, Inc. file with the SEC?

OnKure Therapeutics, Inc. files one 10-K per year and up to three 10-Qs per year. Form 4 insider transactions must be reported within two business days of each trade, so the frequency depends on how often insiders are buying or selling OKUR shares. 8-K filings occur whenever a material event happens — which can be several times per quarter for an active company.

OKUR SEC Filing News — OnKure Therapeutics, Inc.

Latest SEC filings for OnKure Therapeutics, Inc. (OKUR) explained in plain English. Covers insider buying and selling (Form 4), proposed insider sales (Form 144), material company events (8-K), and quarterly & annual reports (10-Q / 10-K). StrongBuyAnalytics provides navigation and brief excerpts or summaries; original filings remain at the SEC/source links and were authored by their filers, not StrongBuyAnalytics. Filing dates shown are source dates. Coverage and detection can be delayed or incomplete because of SEC availability, amendments, parsing, caching, or outages. Latest source filing date shown: 2026-09-23.

OnKure Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on the discovery and development of precision medicines that target biologically validated drivers of cancers and other diseases. Its lead product candidate includes OKI-219, a selective inhibitor of phosphoinositide 3-kinase alpha (PI3Ka) harboring the H1047R mutation that is in Phase 1 clinical trial for the treatment of solid tumors, including breast cancer. The company was founded in 2011 and is headquartered in B…

Sector: Healthcare Industry: Biotechnology Market Cap: $91.1M

Total Filings

Bullish Classifications

Bearish Classifications

Insider Transactions

Material Events (8-K)

Periodic Reports

Rule-based classifications for OKUR currently lean bearish. Of the 20 filing records displayed, 4 carry bearish classifications (such as insider sales or negative 8-K disclosures) versus 0 bullish. This does not necessarily signal fundamental deterioration — insiders sell for many reasons — but it is worth monitoring alongside the company's core financial metrics.

OKUR Filing Activity Snapshot 2026-06-08 — 2026-09-23

Insider Transactions (Form 4)

0 buys vs 4 sells

Net insider selling in this period — insiders sell for many reasons beyond conviction.

Largest Form 144 Filing

$1.3K

Leverone Jason A. (Chief Financial Officer) · 2026-06-24

303 shares · Form 4

Insider Transactions 17 · Forms 3, 4 and 5

A Form 4 is filed within two business days of a company insider — an officer, a director, or a holder of more than ten percent of the stock — changing their position in the shares. All 17 filings in this group are Form 4s for OnKure Therapeutics, Inc.

The difficulty with reading these filings as a group is that a single form type covers transactions that mean entirely different things. An executive spending their own money to buy stock and an executive having shares withheld to pay tax on a vesting grant both appear as a Form 4. Every filing below is therefore tagged with the nature of the underlying transaction, taken from the transaction code reported on the form itself.

Across the 17 insider filings shown, the breakdown is 13 compensation award and 4 open-market sale. 4 of them involved a discretionary open-market trade; the rest are compensation and administrative mechanics.

What each transaction type means

Compensation award ×13: Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.
Open-market sale ×4: The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Form 4 Open-market sale Insider Selling 2026-09-23

OKUR insider Saccomano Nicholas A (Director, President and CEO) sold 87 shares (~$258.76)

Saccomano Nicholas A, listed as Director, President and CEO at OnKure Therapeutics, Inc., reported an open-market sale of 87 OKUR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	87	$2.97	$258.76

Filing: Form 4 (Insider Transaction) Insider: Saccomano Nicholas A (Director, President and CEO) Shares: 87 Est. Value: $258.76

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-09-23

OKUR insider Leverone Jason A. (Chief Financial Officer) sold 302 shares (~$898.21)

Leverone Jason A., listed as Chief Financial Officer at OnKure Therapeutics, Inc., reported an open-market sale of 302 OKUR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	302	$2.97	$898.21

Filing: Form 4 (Insider Transaction) Insider: Leverone Jason A. (Chief Financial Officer) Shares: 302 Est. Value: $898.21

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-11

OKUR insider Form 4 filed for equity award, exercise, or tax withholding

Mathers Edward T (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	22,350	—	—

Filing: Form 4 (Insider Transaction) Insider: Mathers Edward T (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-11

OKUR insider Form 4 filed for equity award, exercise, or tax withholding

Ratcliffe Liam (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	22,350	—	—

Filing: Form 4 (Insider Transaction) Insider: Ratcliffe Liam (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-11

OKUR insider Form 4 filed for equity award, exercise, or tax withholding

Phillips Andrew John (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	22,350	—	—

Filing: Form 4 (Insider Transaction) Insider: Phillips Andrew John (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-11

OKUR insider Form 4 filed for equity award, exercise, or tax withholding

Manke Isaac (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	300,000	—	—
`D`	Disposition to issuer derivative · Stock Option (right to buy)	15,300	—	—
`A`	Compensation award derivative · Stock Option (right to buy)	15,300	—	—

Filing: Form 4 (Insider Transaction) Insider: Manke Isaac (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-11

OKUR insider Form 4 filed for equity award, exercise, or tax withholding

Jansen Valerie Malyvanh (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	22,350	—	—

Filing: Form 4 (Insider Transaction) Insider: Jansen Valerie Malyvanh (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-11

OKUR insider Form 4 filed for equity award, exercise, or tax withholding

GREY MICHAEL G (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	22,350	—	—

Filing: Form 4 (Insider Transaction) Insider: GREY MICHAEL G (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-11

OKUR insider Form 4 filed for equity award, exercise, or tax withholding

Carruthers R Michael (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	22,350	—	—

Filing: Form 4 (Insider Transaction) Insider: Carruthers R Michael (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-11

OKUR insider Form 4 filed for equity award, exercise, or tax withholding

Saccomano Nicholas A (Director, President and CEO) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Employee Stock Option (right to buy)	150,000	—	—
`D`	Disposition to issuer derivative · Employee Stock Option (right to buy)	2,359	—	—
`A`	Compensation award derivative · Employee Stock Option (right to buy)	2,359	—	—
`D`	Disposition to issuer derivative · Employee Stock Option (right to buy)	1,485	—	—
`A`	Compensation award derivative · Employee Stock Option (right to buy)	1,485	—	—
`D`	Disposition to issuer derivative · Employee Stock Option (right to buy)	8,449	—	—
`A`	Compensation award derivative · Employee Stock Option (right to buy)	8,449	—	—
`D`	Disposition to issuer derivative · Employee Stock Option (right to buy)	16,898	—	—
`A`	Compensation award derivative · Employee Stock Option (right to buy)	16,898	—	—
`D`	Disposition to issuer derivative · Employee Stock Option (right to buy)	542,232	—	—
`A`	Compensation award derivative · Employee Stock Option (right to buy)	542,232	—	—

Filing: Form 4 (Insider Transaction) Insider: Saccomano Nicholas A (Director, President and CEO)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-11

OKUR insider Form 4 filed for equity award, exercise, or tax withholding

Leverone Jason A. (Chief Financial Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Employee Stock Option (right to buy)	50,000	—	—
`D`	Disposition to issuer derivative · Employee Stock Option (right to buy	5,781	—	—
`A`	Compensation award derivative · Employee Stock Option (right to buy	5,781	—	—
`D`	Disposition to issuer derivative · Employee Stock Option (right to buy)	5,322	—	—
`A`	Compensation award derivative · Employee Stock Option (right to buy)	5,322	—	—
`D`	Disposition to issuer derivative · Employee Stock Option (right to buy)	130,611	—	—
`A`	Compensation award derivative · Employee Stock Option (right to buy)	130,611	—	—

Filing: Form 4 (Insider Transaction) Insider: Leverone Jason A. (Chief Financial Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-11

OKUR insider Form 4 filed for equity award, exercise, or tax withholding

Hartley Dylan (Chief Scientific Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Employee Stock Option (right to buy)	50,000	—	—
`D`	Disposition to issuer derivative · Employee Stock Option (right to buy)	137,603	—	—
`A`	Compensation award derivative · Employee Stock Option (right to buy)	137,603	—	—

Filing: Form 4 (Insider Transaction) Insider: Hartley Dylan (Chief Scientific Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-08-11

OKUR insider Form 4 filed for equity award, exercise, or tax withholding

Agresta Samuel (Chief Medical Officer) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Employee Stock Option (right to buy)	50,000	—	—
`D`	Disposition to issuer derivative · Employee Stock Option (right to buy)	18,588	—	—
`A`	Compensation award derivative · Employee Stock Option (right to buy)	18,588	—	—
`D`	Disposition to issuer derivative · Employee Stock Option (right to buy)	131,396	—	—
`A`	Compensation award derivative · Employee Stock Option (right to buy)	131,396	—	—

Filing: Form 4 (Insider Transaction) Insider: Agresta Samuel (Chief Medical Officer)

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-24

OKUR insider Saccomano Nicholas A (Director, President and CEO) sold 86 shares (~$378.08)

Saccomano Nicholas A, listed as Director, President and CEO at OnKure Therapeutics, Inc., reported an open-market sale of 86 OKUR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	86	$4.40	$378.08

Filing: Form 4 (Insider Transaction) Insider: Saccomano Nicholas A (Director, President and CEO) Shares: 86 Est. Value: $378.08

View on SEC EDGAR → Open Filing Document →

Form 4 Open-market sale Insider Selling 2026-06-24

OKUR insider Leverone Jason A. (Chief Financial Officer) sold 303 shares (~$1.3K)

Leverone Jason A., listed as Chief Financial Officer at OnKure Therapeutics, Inc., reported an open-market sale of 303 OKUR shares in a Form 4 filing. This is a confirmed insider sale, not just a proposed sale notice.

The insider sold shares on the open market. Sales may be discretionary or executed automatically under a pre-arranged Rule 10b5-1 trading plan, and a Form 4 does not always make clear which applies.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`S`	Open-market sale	303	$4.40	$1.3K

Filing: Form 4 (Insider Transaction) Insider: Leverone Jason A. (Chief Financial Officer) Shares: 303 Est. Value: $1.3K

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-08

OKUR insider Form 4 filed for equity award, exercise, or tax withholding

Mathers Edward T (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	7,650	—	—

Filing: Form 4 (Insider Transaction) Insider: Mathers Edward T (Director)

View on SEC EDGAR → Open Filing Document →

Form 4 Compensation award Tax / Compensation Filing 2026-06-08

OKUR insider Form 4 filed for equity award, exercise, or tax withholding

Ratcliffe Liam (Director) filed a Form 4 covering compensation-related activity such as stock awards, option exercises, conversions, or tax withholding. These filings are usually neutral.

Shares were granted as compensation rather than purchased. No cash changed hands, so the filing reflects a pay decision by the company, not a judgement about the price.

Transactions reported on this filing
Code	Nature	Shares	Price	Value
`A`	Compensation award derivative · Stock Option (right to buy)	1,275	—	—

Filing: Form 4 (Insider Transaction) Insider: Ratcliffe Liam (Director)

View on SEC EDGAR → Open Filing Document →

Material Events 2 · Form 8-K

An 8-K reports a material event in the window between scheduled reports. There are 2 in this period for OnKure Therapeutics, Inc. Each 8-K names the item number it is filed under, and that number is the fastest way to tell a routine disclosure from a consequential one.

Item 2.02 is an earnings release, Item 5.02 is a change of directors or officers, and Item 1.01 or 2.01 covers a material agreement or a completed acquisition. Item 7.01 and Item 8.01 are the general-purpose disclosure items and carry no fixed meaning on their own.

Form 8-K Material Company Update 2026-08-13

OKUR filed 8-K — material company event

OnKure Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Form 8-K Material Company Update 2026-08-04

OKUR filed 8-K — material company event

OnKure Therapeutics, Inc. filed an 8-K with the SEC reporting a material event. Summary unavailable — view the original SEC filing for the full text.

Filing: 8-K (Material Event)

View on SEC EDGAR → Open Filing Document →

Periodic Reports 1 · Forms 10-K and 10-Q

The periodic reports are where the audited and reviewed financial statements live. This period contains 1 quarterly report (10-Q) for OnKure Therapeutics, Inc.

The two are not equivalent in weight. A 10-K is audited by an external firm and includes the full risk factor disclosure, business description and management discussion; a 10-Q is unaudited, reviewed rather than examined, and much shorter. When a figure in a quarterly report is later revised, the annual report is usually where the correction appears.

An amended report — 10-K/A or 10-Q/A — restates or corrects something in the original filing, and is worth reading against the version it replaces.

Form 10-Q Quarterly Report 2026-08-04

OKUR filed Quarterly Report (10-Q)

OnKure Therapeutics, Inc. filed its quarterly report with the SEC. This report includes unaudited financial statements and management discussion for the quarter.

Filing: 10-Q (Quarterly Report)

View on SEC EDGAR → Open Filing Document →

How we classify OnKure Therapeutics, Inc.'s filings

Straight from EDGAR

Each displayed record links to an original source document. StrongBuyAnalytics provides navigation and brief excerpts or summaries, not the filing itself. Parsing may omit context or contain errors, so read the original document in full.

Transaction codes, not guesswork

The nature shown on each insider filing comes from the transaction code the filer entered on the form itself — P for an open-market purchase, A for a compensation award, F for shares withheld to pay tax, M for an option exercise. Where one filing contains several codes, the transaction table lists them line by line.

Why the distinction matters

Insider activity is routinely summarised as buying or selling, which flattens together decisions that mean very different things. Shares withheld for tax on a vesting grant are an automatic administrative step; shares bought on the open market are someone committing their own money at the current price.

What this page does not tell you

A filing records what happened, not why. Form 4 does not always disclose whether a sale was executed under a pre-arranged Rule 10b5-1 plan, and no single filing is a basis for a decision on OKUR. Read these alongside the fundamentals rather than in isolation.

Frequently Asked Questions — OKUR SEC Filings

More Tools for OKUR

OKUR Full Stock Analysis OKUR Live Chart Institutional Ownership Earnings Calendar Options Flow Scanner Semiconductor Demand Zone Tracker Sector Scanner Browse All Stocks

Want deeper OKUR analysis?

View valuation, growth metrics, the rule-based stock-page score, demand zones, peer comparison, and more — all on the OKUR stock analysis page.

OKUR Full Analysis

Publisher, sources & limitations — September 15, 2026. StrongBuyAnalytics provides navigation and brief excerpts or summaries for educational use. Original filings remain at SEC EDGAR or other displayed source links; StrongBuyAnalytics does not author them. Filing dates are source dates, not publication dates for this page. Coverage can be delayed, incomplete, amended, or unavailable because of SEC/source availability, parsing, caching, or outages. Verify every material statement in the original filing.

Data Sources · Methodology · AI Disclosure · Corrections Policy · Disclaimer